We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Unveils Biosimilar Plans Amid Questions of Brand-Drug Bullying
Amgen Unveils Biosimilar Plans Amid Questions of Brand-Drug Bullying
February 12, 2013
Amid accusations of follow-on biologic blocking, Amgen has unveiled plans to develop half a dozen biosimilar products by 2017 as part of its long-term global growth strategy.